Scarica l'app Stockscreener
36.00
0.55%
-0.20
Dopo l'orario di chiusura:
36.00
Precedente Chiudi:
$36.20
Aprire:
$36.73
Volume 24 ore:
465.64K
Relative Volume:
0.72
Capitalizzazione di mercato:
$1.16B
Reddito:
$4.85M
Utile/perdita netta:
$-114.75M
Rapporto P/E:
-11.08
EPS:
-3.25
Flusso di cassa netto:
$-100.36M
1 W Prestazione:
+3.60%
1M Prestazione:
-3.92%
6M Prestazione:
+89.67%
1 anno Prestazione:
+28.71%
Intervallo 1D:
$35.66
$38.66
Intervallo di 1 settimana:
$33.34
$38.66
Portata 52W:
$13.37
$40.16
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Nome
Dianthus Therapeutics Inc
Settore
Industria
Telefono
929-999-4055
Indirizzo
7 TIMES SQUARE, NEW YORK
Confronta DNTH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
36.00 | 1.42B | 4.85M | -114.75M | -100.36M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-02 | Iniziato | William Blair | Outperform |
| 2024-12-20 | Iniziato | TD Cowen | Buy |
| 2024-10-03 | Iniziato | Oppenheimer | Outperform |
| 2024-07-26 | Iniziato | Robert W. Baird | Outperform |
| 2024-06-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-16 | Iniziato | H.C. Wainwright | Buy |
| 2024-02-15 | Iniziato | Stifel | Buy |
| 2023-12-26 | Iniziato | Jefferies | Buy |
| 2023-11-22 | Iniziato | Wedbush | Outperform |
| 2023-10-30 | Iniziato | Guggenheim | Buy |
| 2023-09-28 | Iniziato | Raymond James | Outperform |
| 2022-08-25 | Downgrade | Goldman | Buy → Neutral |
| 2022-01-06 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-08-20 | Ripresa | Goldman | Neutral |
| 2021-08-03 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-07-22 | Reiterato | B. Riley Securities | Buy |
| 2021-06-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-18 | Iniziato | B. Riley Securities | Buy |
| 2021-01-07 | Iniziato | Mizuho | Buy |
| 2020-06-08 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-03-25 | Downgrade | Goldman | Buy → Neutral |
| 2019-03-15 | Iniziato | Raymond James | Outperform |
Mostra tutto
Dianthus Therapeutics Inc Borsa (DNTH) Ultime notizie
Dianthus Therapeutics stock price target raised to $60 by Oppenheimer - Investing.com Canada
Dianthus to license autoimmune disease candidate in a deal worth up to $1B (DNTH:NASDAQ) - Seeking Alpha
Leads Biolabs joins a $1B development deal with Dianthus - BioWorld MedTech
Dianthus Therapeutics Enters Into Exclusive DNTH212 Licensing Deal With Nanjing Leads Biolabs - Nasdaq
Dianthus Enters License Agreement for Autoimmune Drug; Shares Rise - MarketScreener
Dianthus Therapeutics Initiates Licensing Agreement for DNTH212, a Promising Treatment for Autoimmune Diseases with Unique Mechanism of Action - Quiver Quantitative
Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a ... - Bluefield Daily Telegraph
Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases - Stock Titan
Dianthus Therapeutics Strikes Deal For New Autoimmune Drug Rights - Finimize
What candlestick patterns are forming on Dianthus Therapeutics Inc.Dip Buying & Daily Market Momentum Tracking - newser.com
Why retail investors pile into Dianthus Therapeutics Inc. stockJuly 2025 PreEarnings & Real-Time Buy Zone Alerts - newser.com
Dianthus Therapeutics (NASDAQ:DNTH) Earns Buy Rating from Analysts at Truist Financial - MarketBeat
Truist Securities initiates coverage on Dianthus Therapeutics stock with Buy rating - Investing.com
Can Dianthus Therapeutics Inc. stock hit analyst price targetsWeekly Investment Recap & Consistent Return Investment Signals - newser.com
Published on: 2025-10-13 08:04:31 - newser.com
Published on: 2025-10-13 07:23:46 - newser.com
What analysts say about Dianthus Therapeutics Inc stockStock Split Announcements & Free Navigate Market With Precision - earlytimes.in
Is Dianthus Therapeutics Inc. (87E) stock at risk of policy regulationTake Profit & Fast Momentum Entry Tips - newser.com
When is the best time to exit Dianthus Therapeutics Inc.Earnings Trend Report & Weekly High Conviction Ideas - newser.com
How Dianthus Therapeutics Inc. stock benefits from global expansionTreasury Yields & Real-Time Stock Entry Alerts - newser.com
Weiss Ratings Reaffirms "Sell (D-)" Rating for Dianthus Therapeutics (NASDAQ:DNTH) - MarketBeat
Is Dianthus Therapeutics Inc. (87E) stock a buy before new product rolloutQuarterly Growth Report & Fast Entry Momentum Trade Alerts - newser.com
Dianthus Therapeutics Experiences Revision in Its Stock Evaluation Amid Mixed Performance Indicators - Markets Mojo
Volume spikes in Dianthus Therapeutics Inc. stock – what they meanMarket Sentiment Summary & Free Weekly Chart Analysis and Trade Guides - newser.com
Will Dianthus Therapeutics Inc. continue its uptrendInsider Buying & AI Enhanced Trading Signals - newser.com
Why Dianthus Therapeutics Inc. is moving todayTrade Risk Report & Free Long-Term Investment Growth Plans - newser.com
How Does Pritish Nandy Communications Ltd Compare to SP500 Over the Last 3 YearsFibonacci Extensions & Weekly Consultation With Financial Pros - earlytimes.in
What drives Dianthus Therapeutics Inc 87E stock priceDividend Growth Stocks & Free Expert Guidance For Growth - earlytimes.in
Advanced analytics toolkit walkthrough for Dianthus Therapeutics Inc.Market Sentiment Review & Safe Swing Trade Setup Alerts - newser.com
What Wall Street predicts for Dianthus Therapeutics Inc. stock priceQuarterly Earnings Report & Safe Capital Growth Tips - newser.com
What technical models suggest about Dianthus Therapeutics Inc.’s comebackJuly 2025 Rallies & Comprehensive Market Scan Reports - newser.com
Can Dianthus Therapeutics Inc. stock resist sector downturnsSell Signal & High Return Trade Opportunity Guides - newser.com
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 4.9%What's Next? - MarketBeat
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting - The Manila Times
Phase 2 Myasthenia Gravis Trial Results: Dianthus' Claseprubart Data to Be Unveiled at Major Conference - Stock Titan
Dianthus Therapeutics Hits New 52-Week High of $40.16 - Markets Mojo
What drives Okinawa Cellular Telephone Company OCU stock priceAnalyst Upgrades & High Profit Stock Alerts - earlytimes.in
Dianthus Therapeutics stock hits 52-week high at 40.0 USD By Investing.com - Investing.com Nigeria
Dianthus Therapeutics (DNTH) Hits New High as Drug Trial Sparks Optimism for Blockbuster Potential - MSN
Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target - MSN
Dianthus Therapeutics Inc Azioni (DNTH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Dianthus Therapeutics Inc Azioni (DNTH) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Savitz Ryan | CFO & CBO |
Sep 09 '25 |
Sale |
35.00 |
20,000 |
700,000 |
0 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):